Carla J. Lundi

FDA investigator

Appears on 9 documents from 2009 to 2021, mostly at sites in California. Most often cites general requirements (21 CFR 211.160).

9
Documents on file
5.3
Observations per 483
2009
First seen
2021
Most recent

What they cite most

From 48 observations

Activity by year

2009: 1, 2010: 1, 2012: 1, 2015: 4, 2021: 2

Where

California 8 · India 1

Is Carla J. Lundi coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

9 documents, newest first
FirmOpen
483 Revance Therapeutics, IncOct 12, 2021 · Newark, California
483 Revance Therapeutics, Inc.Jul 2, 2021 · Newark, California
483 Universal Packaging SystemsDec 22, 2015 · Chino, California
483 Discus Dental LLCNov 23, 2015 · Ontario, California
483 AmgenMay 22, 2015 · Thousand Oaks, California
483 GLAND PHARMA LIMITEDMar 17, 2015 · Hyderabad, India
483 Teva Parenteral Medicines, Inc.Apr 24, 2012 · Irvine, California

About this profile

What does Carla J. Lundi inspect?

Carla J. Lundi appears on 9 documents on file covering 8 sites, mostly in California.

What do they cite most often?

21 CFR 211.160 (general requirements), followed by 21 CFR 211.192 and 21 CFR 211.42.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Carla J. Lundi is dated Oct 12, 2021.